Consistent with these findings, our study shows that miR-146a is significantly downregulated in six melanoma cell lines with acquired resistance and poorly expressed in two lines derived from drug-resistant tumors, and that its overexpression can restore sensitivity to BRAF/MEKi treatment by affecting both cell proliferation and apoptosis although with a different effect extent in the studied cell lines. The gene discussed is BRAF; the disease is melanoma.